179 related articles for article (PubMed ID: 30203965)
41. Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Coleman AE; Geula C; Price BH; Mesulam MM
Brain Res; 1992 Nov; 596(1-2):340-4. PubMed ID: 1467998
[TBL] [Abstract][Full Text] [Related]
42. Customized fluorescent probe for peering into the expression of butyrylcholinesterase in thyroid cancer.
Kang W; Ma M; Xu L; Tang S; Li J; Ma P; Song D; Sun Y
Anal Chim Acta; 2023 Nov; 1282():341932. PubMed ID: 37923409
[TBL] [Abstract][Full Text] [Related]
43. Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease.
Rice SG; Nowak L; Duysen EG; Lockridge O; Lahiri DK; Reyes PF
J Alzheimers Dis; 2007 Jul; 11(4):481-9. PubMed ID: 17656828
[TBL] [Abstract][Full Text] [Related]
44. A direct assay of butyrylcholinesterase activity using a fluorescent substrate.
Kang S; Lee S; Yang W; Seo J; Han MS
Org Biomol Chem; 2016 Sep; 14(37):8815-8820. PubMed ID: 27714157
[TBL] [Abstract][Full Text] [Related]
45. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
[TBL] [Abstract][Full Text] [Related]
46. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
47. Ratiometric imaging of butyrylcholinesterase activity in mice with nonalcoholic fatty liver using an AIE-based fluorescent probe.
Xiang C; Xiang J; Yang X; Li C; Zhou L; Jiang D; Peng Y; Xu Z; Deng G; Zhu B; Zhang P; Cai L; Gong P
J Mater Chem B; 2022 Jun; 10(22):4254-4260. PubMed ID: 35583194
[TBL] [Abstract][Full Text] [Related]
48. Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.
Johnson ND; Duysen EG; Lockridge O
Neurotoxicology; 2009 May; 30(3):386-92. PubMed ID: 19442823
[TBL] [Abstract][Full Text] [Related]
49. Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.
Ha ZY; Mathew S; Yeong KY
Curr Protein Pept Sci; 2020; 21(1):99-109. PubMed ID: 31702488
[TBL] [Abstract][Full Text] [Related]
50. Anti-Alzheimers activity and molecular mechanism of albumin-derived peptides against AChE and BChE.
Yu Z; Wu S; Zhao W; Ding L; Fan Y; Shiuan D; Liu J; Chen F
Food Funct; 2018 Feb; 9(2):1173-1178. PubMed ID: 29363710
[TBL] [Abstract][Full Text] [Related]
51. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
52. Near-infrared Fluorescence Ocular Imaging (NIRFOI) of Alzheimer's Disease.
Yang J; Yang J; Li Y; Xu Y; Ran C
Mol Imaging Biol; 2019 Feb; 21(1):35-43. PubMed ID: 29802553
[TBL] [Abstract][Full Text] [Related]
53. Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse.
Maurice T; Strehaiano M; Siméon N; Bertrand C; Chatonnet A
Behav Brain Res; 2016 Jan; 296():351-360. PubMed ID: 26306824
[TBL] [Abstract][Full Text] [Related]
54. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
Mesulam M; Guillozet A; Shaw P; Quinn B
Neurobiol Dis; 2002 Feb; 9(1):88-93. PubMed ID: 11848688
[TBL] [Abstract][Full Text] [Related]
55. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.
Podoly E; Shalev DE; Shenhar-Tsarfaty S; Bennett ER; Ben Assayag E; Wilgus H; Livnah O; Soreq H
J Biol Chem; 2009 Jun; 284(25):17170-17179. PubMed ID: 19383604
[TBL] [Abstract][Full Text] [Related]
56. Dual-Mode Ratiometric Electrochemical and Turn-On Fluorescent Detection of Butyrylcholinesterase Utilizing a Single Probe for the Diagnosis of Alzheimer's Disease.
Dong H; Zhao L; Wang T; Chen Y; Hao W; Zhang Z; Hao Y; Zhang C; Wei X; Zhang Y; Zhou Y; Xu M
Anal Chem; 2023 May; 95(21):8340-8347. PubMed ID: 37192372
[TBL] [Abstract][Full Text] [Related]
57. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
58. Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase.
Wang Y; Boeck AT; Duysen EG; Van Keuren M; Saunders TL; Lockridge O
Toxicol Appl Pharmacol; 2004 May; 196(3):356-66. PubMed ID: 15094306
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Ghobadian R; Nadri H; Moradi A; Bukhari SNA; Mahdavi M; Asadi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Sharifzadeh M; Amini M
Bioorg Med Chem; 2018 Sep; 26(17):4952-4962. PubMed ID: 30190181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
